Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

New Therapeutic Approach for Central Nervous System Lymphoma By Intracerebroventricular Delivery of CD19CAR T Cells

Xiuli Wang, MD PhD, Ryan Urak, MS, Walter Miriam, MS, Laura Lim, BS, Brenda Aguilar, BS, Alfonso Brito, BS, Aniee Sarkissian, BS, Christine Brown, PhD, Sandra H. Thomas, PhD, Leslie Popplewell, MD, Lihua E. Budde, MD PhD, Stephen J. Forman, MD

Blood (2016) 128 (22): 2161.

https://doi.org/10.1182/blood.V128.22.2161.2161

Published: 2016

Journal Articles

Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor Redirected-T Cells Against Multiple Myeloma

Xiuli Wang, MD PhD, Ryan Urak, MS, Miriam Walter, MS, Lihong Weng, MD, Laura Lim, BS, Ching Wong, BS, Wen-Chung Chang, MS, Sandra H. Thomas, PhD, Myo Htut, MD, Amrita Krishnan, MD, Stephen J. Forman, MD

Blood (2016) 128 (22): 812.

https://doi.org/10.1182/blood.V128.22.812.812

Published: 2016

Journal Articles

Phase 1 studies of central memory–derived CD19 CAR T–cell therapy following autologous HSCT in patients with B-cell NHL

Blood (2016) 127 (24): 2980–2990.

https://doi.org/10.1182/blood-2015-12-686725

Published: 2016

Includes: Supplemental data

Journal Articles

Interim Analysis of a Phase 2 Study of Bortezomib Plus Rituximab Maintenance Therapy in Patients with Mantle Cell Lymphoma Status Post Autologous Stem Cell Transplantation

Robert Chen, Joycelynne Palmer, PhD, Leona Holmberg, Jessica Alluin, Pritsana Chomchan, PhD, Leslie L. Popplewell, MD, Tanya Siddiqi, MD, Sandra H. Thomas, PhD, Kathryn Irenze, Auayporn P. Nademanee, MD, Ricardo Spielberger, MD, John J Rossi, Steven T. Rosen, MD, Larry W. Kwak, MD, Stephen J. Forman, MD

Blood (2015) 126 (23): 1961.

https://doi.org/10.1182/blood.V126.23.1961.1961

Published: 2015

Journal Articles

Phase I Studies of Cellular Immunotherapy Using Central Memory Derived-CD19-Specific T Cells Following Autologous Stem Cell Transplantation for Patients with High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma

Leslie Popplewell, MD, Xiuli Wang, PhD, Araceli Naranjo, BS, Suzette Blanchard, PhD, Jamie Wagner, BS, ChingLam Wong, BS, Ryan Urak, MS, Wen-Chung Chang, MS, Samer K Khaled, MD, Tanya Siddiqi, MD, Elizabeth E. Budde, MD PhD, Jingying Xu, PhD, Brenda Chang, BS, Sandra H. Thomas, PhD, Stanley R. Riddell, MD, Christine Brown, PhD, Michael C Jensen, MD, Stephen J. Forman, MD

Blood (2015) 126 (23): 930.

https://doi.org/10.1182/blood.V126.23.930.930

Published: 2015

Journal Articles

Ex Vivo AKT Inhibition Promotes the Generation of Potent CD19CAR T Cells for Adoptive Immunotherapy

Ryan Urak, MS, ChingLam Wong, BS, Wen-Chung Chang, MS, Elizabeth E. Budde, MD PhD, Christine Brown, PhD, Sandra H. Thomas, PhD, Stephen J. Forman, MD, Xiuli Wang, PhD

Blood (2015) 126 (23): 3086.

https://doi.org/10.1182/blood.V126.23.3086.3086

Published: 2015

Journal Articles

Reduced Relapse Risk in Acute Myelogenous Leukemia (AML) after Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in Patients Who Experienced CMV Reactivation: Influence of Donor KIR Genotypes

Anthony Stein, Ketevan Gendzekhadze, PhD, Joycelynne Palmer, PhD, Ni-Chun Tsai, MS MPH, Sandra H. Thomas, PhD, Stephen J. Forman, John A. Zaia, MD, David Senitzer, PhD, Ryotaro Nakamura, MD

Blood (2014) 124 (21): 669.

https://doi.org/10.1182/blood.V124.21.669.669

Published: 2014

Journal Articles

Drug Metabolism Gene Polymorphisms Influence Tacrolimus/Sirolimus Blood Levels and Incidence of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation

Samer K Khaled, MD, Joycelynne Palmer, PhD, Josef Herzog, Tracey Stiller, MS, Ni-Chun Tsai, MS MPH, David Senitzer, PhD, Xueli Liu, PhD, Sandra H. Thomas, PhD, Sepideh Shayani, PharmD, Jeffrey Weitzel, MD, Stephen J. Forman, Ryotaro Nakamura, MD

Blood (2014) 124 (21): 2492.

https://doi.org/10.1182/blood.V124.21.2492.2492

Published: 2014

Journal Articles

Mycophenolate Mofitil (MMF) As Salvage Graft-Versus-Host Diseases (GVHD) Prophylaxis In Allogeneic Hematopoietic Stem Cell Transplantation (HCT) After Early Discontinuation Of Tacrolimus and/Or Sirolimus Due To Toxicities

Haris Ali, MD, Joycelynne Palmer, PhD, Zeynep Eroglu, MD, Tracey Stiller, Sandra H. Thomas, PhD, Samer Khaled, MBBCH, MD, Sepideh Shayani, Pharm.D., Pablo Parker, MD, Stephen J. Forman, MD, Ryotaro Nakamura, MD

Blood (2013) 122 (21): 5478.

https://doi.org/10.1182/blood.V122.21.5478.5478

Published: 2013

Journal Articles

Brentuximab Vedotin Improves HCT-CI, CR Status, and Peri-Transplant Toxicity In Patients With Relapsed/Refractory Hodgkin Lymphoma Heading To RIC Allo-HCT

Robert Chen, MD, Joycelynne Palmer, PhD, Ni-Chun Tsai, MS MPH, Sandra H. Thomas, PhD, Tanya Paris, Leslie Popplewell, MD, Chatchada Karanes, MD, Tanya Siddiqi, MD, Auayporn Nademanee, MD, Ji-Lian Cai, MD, Stephen J. Forman, MD

Blood (2013) 122 (21): 3374.

https://doi.org/10.1182/blood.V122.21.3374.3374

Published: 2013

Journal Articles

Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL

Robert W. Chen, MD, Joycelynne Palmer, PhD, Tanya Siddiqi, MD, Sandra H. Thomas, PhD, Young Kim, MD, Chen T Binhong, MD, Amrita Krishnan, MD, Nitya Nathwani, MD, Ji-Lian Cai, MD, PhD, Michelle Mott, RN, Deron Matsuoka, BS, Stephen J Forman, MD

Blood (2012) 120 (21): 3699.

https://doi.org/10.1182/blood.V120.21.3699.3699

Published: 2012

Journal Articles

Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma

Robert Chen, Joycelynne M. Palmer, Sandra H. Thomas, Ni-Chun Tsai, Len Farol, Auayporn Nademanee, Stephen J. Forman, Ajay K. Gopal

Blood (2012) 119 (26): 6379–6381.

https://doi.org/10.1182/blood-2012-03-418673

Published: 2012

Journal Articles

Phase 1/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies

Joseph Rosenthal, Jeffrey Wong, Anthony Stein, Dajun Qian, Debbie Hitt, Hossameldin Naeem, Andrew Dagis, Sandra H. Thomas, Stephen Forman

Blood (2011) 117 (1): 309–315.

https://doi.org/10.1182/blood-2010-06-288357

Published: 2011

NARROW

New Therapeutic Approach for Central Nervous System Lymphoma By Intracerebroventricular Delivery of CD19CAR T Cells

Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor Redirected-T Cells Against Multiple Myeloma

Phase 1 studies of central memory–derived CD19 CAR T–cell therapy following autologous HSCT in patients with B-cell NHL

Interim Analysis of a Phase 2 Study of Bortezomib Plus Rituximab Maintenance Therapy in Patients with Mantle Cell Lymphoma Status Post Autologous Stem Cell Transplantation

Phase I Studies of Cellular Immunotherapy Using Central Memory Derived-CD19-Specific T Cells Following Autologous Stem Cell Transplantation for Patients with High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma

Ex Vivo AKT Inhibition Promotes the Generation of Potent CD19CAR T Cells for Adoptive Immunotherapy

Reduced Relapse Risk in Acute Myelogenous Leukemia (AML) after Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in Patients Who Experienced CMV Reactivation: Influence of Donor KIR Genotypes

Drug Metabolism Gene Polymorphisms Influence Tacrolimus/Sirolimus Blood Levels and Incidence of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation

Mycophenolate Mofitil (MMF) As Salvage Graft-Versus-Host Diseases (GVHD) Prophylaxis In Allogeneic Hematopoietic Stem Cell Transplantation (HCT) After Early Discontinuation Of Tacrolimus and/Or Sirolimus Due To Toxicities

Brentuximab Vedotin Improves HCT-CI, CR Status, and Peri-Transplant Toxicity In Patients With Relapsed/Refractory Hodgkin Lymphoma Heading To RIC Allo-HCT

Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL

Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma

Phase 1/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only